#USA #Los Angeles #Alzheimer's #Spinogenix #Tazbentetol

Spinogenix Achieves Milestone with WHO Approval of Tazbentetol

On December 1, 2025,
Spinogenix, Inc., a pioneering biopharmaceutical company, announced the approval of 'tazbentetol' by the World Health Organization (WHO) as the official non-proprietary name for its revolutionary drug, previously known as SPG302. This marks a significant step forward in the journey towards developing innovative treatments for patients suffering from neurodegenerative diseases.

A New Hope for Patients

Tazbentetol is an oral investigational therapy specifically designed to combat neurodegenerative and psychiatric disorders, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), schizophrenia, and glaucoma. Its unique mechanism focuses on restoring synaptic function, which is crucial for maintaining cognitive and motor skills. By enhancing the synapses—vital connections between neurons—tazbentetol aims to reverse the cognitive decline experienced by many patients suffering from these conditions.

Dr. Stella Sarraf, CEO and Founder of Spinogenix, emphasized the importance of this approval by stating, “Receiving the non-proprietary name tazbentetol is a crucial milestone in the development and potential commercialization of our synaptic regenerative therapies.” This newfound recognition not only represents a critical step forward in the drug’s journey but also offers hope to patients looking for effective treatments.

The Research Behind Tazbentetol

Tazbentetol's innovative approach is rooted in synaptic regeneration, a relatively new frontier in the treatment of neurodegenerative disorders. The therapy targets the underlying issues associated with diseases like Alzheimer's and ALS by fostering the creation of new synapses, thereby revitalizing the brain's ability to think, plan, and control bodily movements.

Currently, tazbentetol is undergoing crucial testing phases, with results from the Phase 2a trials for Alzheimer's and ALS expected to be unveiled during key conferences this week. Additionally, enrollment for the ongoing Phase 2 clinical trial in schizophrenia is nearing completion. The anticipated outcomes of these studies could unlock further insights into the drug's efficacy and transformative potential.

Understanding the Importance of INN Approval

The World Health Organization's approval of the International Nonproprietary Name (INN) for pharmaceutical substances is pivotal. An INN is a globally recognized name that ensures clarity in prescribing, dispensing, and identifying medications for patients. The approval of tazbentetol aligns with the WHO's standards for unique naming practices, further solidifying Spinogenix's commitment to patient safety and the pharmaceutical industry’s regulatory framework.

A Shift in Treatment Philosophy

The current landscape of treatments for neurodegenerative conditions primarily revolves around symptom management and slowing disease progression. Spinogenix aims to shift this paradigm by offering treatments that provide real hope for restoring lost functions. With both tazbentetol and the ongoing development of another therapeutic candidate, SPG601, which targets Fragile X Syndrome, Spinogenix is at the forefront of transforming how these challenging diseases are approached.

Through innovative research and commitment to patient health, Spinogenix strives to provide not only effective therapies but also renewed hope to patients and their families. The company’s ongoing endeavors reflect a future where neuroscience can significantly alter the trajectories of neurodegenerative, neuropsychiatric, and neurodevelopmental disorders, making a profound difference in people's lives.

Conclusion

With the recent approval of tazbentetol by the WHO, Spinogenix is poised to lead a new wave of treatments that address the root causes of debilitating diseases. As research progresses and results from clinical trials emerge, the potential for tazbentetol to change lives becomes increasingly tangible. The future looks promising for those affected by neurodegenerative disorders, thanks to the innovative spirit and dedication of Spinogenix.

For more information about Spinogenix and their groundbreaking work, visit their website: www.spinogenix.com.